Faraday Pharmaceuticals

IN THE PRESS

Press Releases

Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference

November 6, 2024

·

1 min read

Drug Development

Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent

January 4, 2024

·

4 min read

Drug Development

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial InfarctionIocyte AMI-3 Trial

May 10, 2022

·

4 min read

Drug Development

Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart AttackTo be Published in the International Journal of Cardiology

December 27, 2021

·

3 min read

Drug Development

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness

October 14, 2021

·

2 min read

Drug Development

Faraday Pharmaceuticals Announces Positive Top-Line Results from Phase 2 Trial of FDY-5301 for Treatment of Reperfusion Injury Following a STEMI Heart Attack

November 19, 2019

·

3 min read

Drug Development

Faraday Pharmaceuticals Announces Presentation of Clinical Data from Phase 2 Trial of FDY-5301 at the American Heart Association Scientific Sessions 2019

November 12, 2019

·

1 min read

Drug Development

Faraday Pharma Announces First-In-Human Trial Of FDY-5301

September 23, 2016

·

1 min read

JOBS